MMWR. Morbidity and mortality weekly report · 2025
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zambrano Laura D, Simeone Regina M, Newhams Margaret M, Payne Amanda B, Halasa Natasha B, Orzel-Lockwood Amber O, Calixte Jemima M, Kamidani Satoshi, Crandall Hillary, Cameron Melissa A, Schuster Jennifer E, Maddux Aline B, Chiotos Kathleen, Irby Katherine, Shein Steven L, Staat Mary Allen, Martin Lora M, Bhumbra Samina S, Nofziger Ryan A, Chauhan Jigar C, Zerr Danielle M, Gertz Shira J, Guzman-Cottrill Judith A, Kong Michele, Hume Janet R, Coates Bria M, Michelson Kelly N, Levy Emily R, Bradford Tamara T, Schwartz Stephanie P, Walker Tracie C, Stockwell Melissa S, Biggs Austin, Hogan Alexander H, Lindsey Katherine, Campbell Angela P, Randolph Adrienne G, Overcoming RSV Investigators
Аннотация
Respiratory syncytial virus (RSV) is a leading cause of intensive care unit (ICU) admission and respiratory failure among infants (children aged <1 year) in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, to protect against RSV-associated lower respiratory tract infection among all infants aged <8 months born during or entering their first RSV season. Following licensure, nirsevimab effectiveness has been demonstrated against RSV-associated infant hospitalization, but evidence regarding effectiveness against RSV-associated critical illness is limited. In a 27-hospital case-control investigation, nirsevimab effectiveness against both RSV-associated infant ICU admission and acute respiratory failure (illness requiring continuous positive airway pressure, bilevel positive airway pressure, or invasive mechanical ventilation) after hospital admission was evaluated during December 1, 2024-April 15, 2025. Among 457 case-patients who received a positive RSV test result and 302 control patients who received a negative RSV test result admitted to an ICU with respiratory symptoms, 14% and 45%, respectively, had received nirsevimab ≥7 days before symptom onset. Nirsevimab was 80% effective (95% CI = 70%-86%) against RSV-associated ICU admission and 83% effective (95% CI = 74%-90%) against acute respiratory failure when received a median of 52 days (IQR = 32-89 days) and 50 days (IQR = 32-86 days) before onset for each respective endpoint. These estimates support the recommendation for use of nirsevimab as a prevention strategy to protect infants against severe outcomes from RSV infection.